| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year | 
|---|---|---|---|---|---|---|
|  | body size and weight | Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 | 
|  | DXA | Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 | 
|  | genotype assessment | Gpr84 allele assessment. PCR, sequencing. | inbred w/CC8 (58) | both | 6wks | 2013 | 
|  | immune cell quantification | Regulatory T cells (Treg), thymus, spleen. | inbred (33) | m | 5-6wks | 2007 | 
|  | ventilator with methacholine | Airway resistance. Baseline vs. methacholine-challenged (several doses). | inbred (37) | both | 9-12wks | 2010 | 
|  | plethysmography with methacholine | Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 | 
|  | ventilator with methacholine | Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 | 
|  | histopathology | Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. | inbred (28) | both | 87wks | 2011 | 
|  | health assessment with Plasmodium berghei | Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. | inbred (31) | both | 8-12wks | 2010 | 
|  | genotyping | SNP profiling, 131,000+ genomic locations, 1-19,X. | inbred (89) | 2009 | ||
|  | genotyping | SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. | inbred (142) | m | 2014 | |
|  | body size and weight | Body weight and length. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
|  | complete blood count | Hematology. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
|  | DXA | Body mass, fat mass, lean mass, bone mineral density. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
|  | lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
|  | metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
|  | immune cell quantification | Natural killer T cells in peripheral blood, spleen, thymus. | inbred (38) | both | 8-10wks | 2011 | 
|  | behavior observation with haloperidol | Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 | 
|  | body weight with haloperidol | Baseline vs. after haloperidol 60d implant. | inbred w/CC8 (27) | m | 9-28wks | 2012 | 
|  | drug and metabolite quantification with haloperidol | Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 | 
|  | inclined screen test with haloperidol | Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 | 
|  | open field test with haloperidol | Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. | inbred w/CC8 (27) | m | 9-28wks | 2012 | 
|  | in vitro assay with Bacillus anthracis lethal toxin | Bacillus anthracis lethal toxin (anthrax) susceptibility. | inbred (50) | f | 6-8wks* | 1998 | 
|  | urinalysis | Microalbumin, creatinine, ratio. | inbred w/CC7 (34) | m | 10wks | 2012 | 
|  | bottle choice test with ethanol | Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). | inbred (22) | both | 8-12wks | 2007 | 
|  | genotype assessment with Candida albicans | C5 allele sufficiency or deficiency. | inbred (36) | f | 8-12wks | 2011 | 
|  | in vitro assay with Candida albicans | Susceptibility to infection with Candida albicans. | inbred (36) | f | 8-12wks | 2011 | 
|  | body weight | Daily body weight gain of cross-fostered pups. | inbred (31) | f | 14-18wks | 2012 | 
|  | colony observation | Maternal nurturing study. | inbred (31) | f | 14-18wks | 2012 | 
|  | mineral quantification | concentrations of various minerals in milk | inbred (31) | f | 14-20wks | 2018 | 
|  | body weight with isoniazid | Body weight. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
|  | histopathology with isoniazid | Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
|  | lipid profile with isoniazid | Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
|  | metabolic panel with isoniazid | Alanine transaminase. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
|  | organ weights with isoniazid | Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
|  | biomarker quantification with DB289 | Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
|  | body weight with DB289 | DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
|  | drug and metabolite quantification with DB289 | Kidney metabolite (DB75) concentration. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
|  | metabolic panel with DB289 | Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
|  | organ weights with DB289 | Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
|  | urinalysis with DB289 | Urine volume, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
|  | bronchoalveolar lavage assessment with radiation | Bronchoalveolar cell differential after exposure to radiation (18 Gy). | inbred (26) | both | 15-36wks | 2012 | 
|  | health assessment with radiation | Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). | inbred (26) | both | 15-36wks | 2012 | 
|  | histopathology with radiation | Post exposure to radiation. | inbred (26) | both | 15-36wks | 2012 | 
|  | ophthalmoscopy | Retinal fundoscopic examination. | inbred w/CC7 (41) | both | 6-7wks | 2008 | 
|  | slit lamp | Eye morphology. Frequency rates of disorders. | inbred w/CC7 (41) | both | 6-7wks | 2008 | 
|  | histopathology | Kidney pathology at 20mo. | inbred (23) | both | 87wks | 2014 | 
|  | DXA | Bone mineral density (whole body, femur, spine). | HMDP (96) | m | 16wks | 2011 | 
|  | metabolite quantification | Liver metabolic profiling. Molecular measures of nucleotides, peptides. 16h fast. | HMDP (106) | m | 16wks | 2014 | 
|  | lipid profile | Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. | HMDP (99) | m | 16wks | 2010 | 
|  | NMR | Percent fat. | HMDP (99) | m | 16wks | 2010 | 
|  | tail cuff | Heart rate and blood pressure. Conscious mice. | HMDP (58) | m | 9-10wks | 2012 | 
|  | fear conditioning test | Contextual fear, cued fear. | HMDP (94) | m | 10wks | 2011 | 
|  | metabolite quantification | Liver metabolic profiling. Molecular measures of amino acids. 16h fast. | HMDP (106) | m | 16wks | 2014 | 
|  | metabolite quantification | Liver metabolic profiling. Molecular measures of carbs, cofactors, vitamins, energy, xenobiotics. 16h fast. | HMDP (106) | m | 16wks | 2014 | 
|  | metabolite quantification | Liver metabolic profiling. Molecular measures of lipids (non-lysolipids). 16h fast. | HMDP (106) | m | 16wks | 2014 | 
|  | metabolite quantification | Liver metabolic profiling. Molecular measures of lipids (lysolipids). 16h fast. | HMDP (106) | m | 16wks | 2014 | 
|  | MHC haplotype tissue typing | Major histocompatibility complex (MHC) H2 haplotype. | inbred (56) | both | 2000 | |
|  | colony observation | Appearance, coat color | inbred (61) | both | 2006 | |
|  | ABR test | Auditory brainstem response. | inbred (51) | both | 3-12wks and 15-72wks | 2000 | 
|  | urinalysis | Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. | inbred (30) | both | 52, 78, 104 wks | 2008 | 
|  | histopathology | Kidney pathology. Aging study, 6mo, 12mo, 20mo. | inbred (29) | m | 52, 78, 104 wks | 2013 | 
|  | open field test | Distance traveled, after first 10 min and after 55 min. | other (58) | both | 7-26wks | 2019 | 
|  | body weight | Body weight | inbred w/CC8 (62) | both | 8-14wks | 2021 | 
|  | open field test | Locomotor activity and grooming behavior. | inbred w/CC8 (62) | both | 8-14wks | 2021 | 
|  | body size and weight | Body length measurements. | inbred w/CC8 (62) | both | 10-20 wks | 2021 | 
|  | gait analysis | Angular velocity, Stride speed, Step length, Step width, and other gait metrics. | inbred w/CC8 (62) | both | 10-20 wks | 2021 | 
|  | open field test | Distance traveled. | inbred w/CC8 (62) | both | 10-20 wks | 2021 | 
|  | body weight | Body weight | inbred (41) | both | 8-9wks | 2010 | 
|  | running wheel monitoring | Distance, duration, speed. | inbred (41) | both | 8-9wks | 2010 | 
|  | body weight | Body weight | inbred (34) | both | 8wks | 2012 | 
|  | treadmill endurance test | Duration, distance, work. | inbred (34) | both | 8wks | 2012 | 
|  | apoptosis assessment | Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 | 
|  | chromosome instability assessment | Chromosome instability. Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 | 
|  | body weight with high-fat diet | High-fat diet for 8wks. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 | 
|  | DXA with high-fat diet | Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 | 
|  | hormone quantification with high-fat diet | Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 | 
|  | metabolic panel with high-fat diet | Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 | 
|  | body weight with high-fat diet | Baseline vs. high-fat diet for 8wks. | inbred (44) | both | 15-19wks | 2000 | 
|  | histopathology with high-fat diet | Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 | 
|  | lipid profile with high-fat diet | Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 | 
|  | metabolic panel with high-fat diet | Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. | inbred (44) | both | 15-19wks | 2000 | 
|  | organ dimensions with high-fat diet | Gallbladder volume after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 | 
|  | organ weights with high-fat diet | Liver weight after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 | 
|  | histopathology with high-fat diet | Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). | inbred w/CC7 (43) | both | 7-9wks, 24-27wks | 2002 | 
|  | lipid profile with high-fat diet | Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. | inbred w/CC7 (43) | both | 7-9wks, 24-27wks | 2002 | 
|  | lipid profile | Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. | inbred w/CC7 (43) | both | 10wks | 2002 | 
|  | coagulation test | Fibrinogen. | inbred w/CC7 (43) | both | 10wks | 2001 | 
|  | complete blood count | Hematology. | inbred w/CC7 (43) | both | 10wks | 2001 | 
|  | complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (30) | both | 26, 52, 78, 104 wks | 2007 | 
|  | complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 | 
|  | immune cell quantification | Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 | 
|  | gait analysis | Aging study, 6mo, 18mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 | 
|  | grip strength | Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 | 
|  | tail cuff | Heart rate and blood pressure. Conscious mice. | inbred (25) | m | 10wks | 2007 | 
|  | study archive | Histopathology. Aging study. | inbred (28) | both | 2008 | |
|  | tail cuff | Heart rate and blood pressure. Conscious mice. | inbred (14) | both | 9wks | 2004 | 
|  | body weight with cocaine | Body weight | inbred (45) | m | 8-11wks | 2015 | 
|  | open field test with cocaine | Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. | inbred (45) | m | 8-11wks | 2015 | 
|  | forced swim test with ovariectomy | Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. | inbred (37) | f | 8-10wks | 2016 | 
|  | open field test with ovariectomy | Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. | inbred (37) | f | 8-10wks | 2016 | 
|  | biomarker quantification with acetaminophen | Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 | 
|  | histopathology with acetaminophen | Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 | 
|  | metabolic panel with acetaminophen | Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 | 
|  | metabolite quantification with acetaminophen | Liver protein homeostasis. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 | 
|  | organ weights with acetaminophen | Liver weight after acetaminophen (several doses) vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 | 
|  | body weight | Body weight | inbred w/CC7 (40) | both | 9-15wks | 2002 | 
|  | bottle choice test | Various salt solutions (several concentrations) vs. water. | inbred w/CC7 (40) | both | 9-15wks | 2002 | 
|  | DXA | Body mass, fat mass, lean mass, bone mineral density and content. | inbred w/CC7 (40) | both | 9-15wks | 2002 | 
|  | metabolic panel | Ionized and total blood calcium, blood pH. | inbred w/CC7 (40) | both | 9-15wks | 2002 | 
|  | monitoring system | Bleeding time to collect approx 30 µL. | inbred w/CC7 (40) | both | 9-15wks | 2002 | 
|  | genotyping | SNP profiling, 132,000+ genomic locations, 1-19,X | HMDP (248) | both | 2018 | |
|  | body weight | Body weight | inbred (21) | both | 6-8wks | 2009 | 
|  | bone dimensions | Craniofacial bone dimensions. | inbred (21) | both | 6-8wks | 2009 | 
|  | acoustic startle test | Acoustic startle response, prepulse inhibition. | inbred w/CC7 (40) | both | 5-6wks | 2002 | 
|  | body weight | Body weight | inbred w/CC7 (40) | both | 5-6wks | 2002 | 
|  | elevated plus maze | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 | 
|  | light-dark box | Light-dark test. Anxiety-related behavior. | inbred (38) | both | 12-14wks | 2010 | 
|  | open field test | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 | 
|  | immune cell quantification with BEZ235, doxorubicin, idarubicin, selumetinib | In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. | inbred w/CC7 (36) | m | 10wks | 2015 | 
|  | ECG | Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. | inbred (29) | both | 26, 52, 87 wks | 2008 | 
|  | body weight | Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 | 
|  | hormone quantification | Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 | 
|  | colony observation | Life span study. Survival curves. Aging study. | inbred (31) | both | max lifespan | 2007 | 
|  | lipid profile | Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. | inbred (32) | both | 26, 52, 78 wks | 2008 | 
|  | metabolic panel | Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. | inbred (32) | both | 26, 52, 78 wks | 2008 | 
|  | colony observation | Observed age at vaginal opening (patency). Aging study. | inbred (33) | f | 2-9wks | 2009 | 
|  | tympanometry | Middle ear function. | inbred (61) | both | 15-51d | 2008 | 
|  | body weight | inbred (30) | both | 7-15 wks | 2020 | |
|  | intake monitoring | Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 | 
|  | monitoring system | Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |